Business
Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update
-NL-201 IND submission anticipated by year end 2020- -Clinical Trial Notification application submitted in Australia- -Ended 3rd quarter with $201.2 million
About this update from Neurogene Inc.
[{"type":"text","content":"-NL-201 IND submission anticipated by year end 2020-\n -Clinical Trial Notification application submitted in Australia- -Ended 3rd quarter with $201.2 million in cash and cash equivalents- SEATTLE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the third quarter ended September 30, 2020. “The past quarter has been highly productive at Neoleukin as we continue to advance NL-201 toward an IND and prepare to initiate our first clinical trial in patients with advanced cancer,” said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. “This represents an important step for Neoleukin and for the field of de novo protein design. In addition, we recently disclosed details about NL-CVX1, a de novo protein designed to bind the spike protein of SARS-CoV-2 and to block viral infection of mammalian cells. These data, published in the journal Science, demonstrate the broad applicability and speed of our de novo design platform to address serious biological problems.” Recent Updates NL-201 – IND on Track, CTN Application Submission in Australia Neoleukin remains focused on its efforts to submit an Investigational New Drug (IND) application for its lead immunotherapy therapeutic candidate, NL-201, an IL-2 and IL-15 agonist, during the fourth quarter of 2020. At this time, Neoleukin does not expect a delay in the submission of its IND due to COVID-19 but acknowledges the potential exists for this timing to be impacted. In addition, the company has submitted a Clinical Trial Notification (CTN) application for NL-201 in Australia. The planned first-in-human clinical trials for NL-201 will test intravenous, monotherapy in patients with advanced solid tumors to determine the safety and tolerability of various dosing regimens. De Novo Protein Design for Coronavirus – NL-CVX1 In November 2020, Neoleukin announced the publication of its scientific work in the journal Science describing the creation of novel molecules designed to treat or prevent infection by SARS-CoV-2, the virus that causes COVID-19. As reported, the optimized, hyperstable proteins act as decoys that bind to the SARS-CoV-2 spike protein with high affinity, pre...